Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial. (2022)
Attributed to:
Low dose interleukin (IL)-2 in patients with a recent acute coronary syndrome
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2022-062602
PubMed Identifier: 36207050
Publication URI: http://europepmc.org/abstract/MED/36207050
Type: Journal Article/Review
Volume: 12
Parent Publication: BMJ open
Issue: 10
ISSN: 2044-6055